4+ hour, 2+ min ago  (419+ words) While the large pharma's new drug Cobenfy has stumbled in schizophrenia, it could find new life in Alzheimer's disease Bristol Myers Squibb is under pressure to make good on its $14 billion acquisition of Karuna Therapeutics, which brought its breakthrough schizophrenia…...